2,400
Participants
Start Date
November 20, 2024
Primary Completion Date
December 15, 2027
Study Completion Date
December 15, 2027
Novel oral poliomyelitis vaccine type 1 (nOPV1)
Live attenuated novel poliomyelitis virus type 1 at two different dosages, containing middle-dose (MD) 10\^6.0, or high-dose (HD) 10\^6.5 CCID₅₀/dose
Novel oral poliomyelitis vaccine type 2 (nOPV2)
Live attenuated novel poliomyelitis virus type 2 administered at low-dose (LD) 10\^5.3 and HD 10\^5.6 CCID₅₀/dose.
Novel oral poliomyelitis vaccine type 3 (nOPV3)
Live attenuated novel poliomyelitis virus type 3 at two different dosages, containing MD 10\^6.0, or HD 10\^6.5 CCID₅₀/dose.
Bivalent Oral Poliomyelitis Vaccine (bOPV)
Live attenuated poliomyelitis viruses types 1 and 3 (Sabin strains). Each dose (2 drops = 0.1 mL) contains not less than 10\^6.0 infective units of type 1 and 10\^5.8 of type 3.
NOT_YET_RECRUITING
International Centre for Diarrhoeal Disease Research, Dhaka
RECRUITING
International Centre for Diarrhoeal Disease Research, Dhaka
Bio Farma, Indonesia
UNKNOWN
PATH
OTHER